A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-08

Study Completion Date

2023-04-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VX-708 in healthy participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants

NCT05653323

Pain

COMPLETED PHASE1

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults

NCT06394167

Pain

COMPLETED PHASE1

A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

NCT06615570

Pain

COMPLETED PHASE1

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

NCT05518734

Pain

COMPLETED PHASE1

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

NCT06226454

Pain

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A: VX-708

Participants will be randomized to receive a single dose of different dose levels of VX-708.

Group Type EXPERIMENTAL

VX-708

Intervention Type DRUG

Solution or suspension for oral administration.

Part A: Placebo

Participants will receive placebo matched to VX-708.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo matched to VX-708 for oral administration.

Part B: VX-708

Participants will be randomized to receive multiple doses of different dose levels of VX-708. The dose levels will be determined based on the data from Part A.

Group Type EXPERIMENTAL

VX-708

Intervention Type DRUG

Solution or suspension for oral administration.

Part B: Placebo

Participants will receive placebo matched to VX-708.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo matched to VX-708 for oral administration.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VX-708

Solution or suspension for oral administration.

Intervention Type DRUG

Placebo

Placebo matched to VX-708 for oral administration.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female of non-childbearing potential are eligible
* Body mass index (BMI) of 18.0 to 32.0 kilograms per meter square (kg/m\^2)
* A total body weight greater than (\>) 50 kg

Exclusion Criteria

* History of febrile illness or other acute illness within 14 days before the first dose of study drug
* Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
* History of cardiac dysrhythmias

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes